Article
Organizations work to streamline approval of prostate cancer drugs
Four leading prostate cancer advocacy groups are working in cooperation with the FDA to streamline the approval process of critical prostate cancer treatments by changing clinical trial endpoints, without compromising safety.
Related Videos
Study findings highlight gender gaps in oncology authorship and citation
NMIBC Treatment Decisions in the Age of BCG Shortages
Current Standards of Care and Shifting Strategies in NMIBC
Andrew Armstrong, MD, previews key prostate cancer data at ASCO 2025
BLUES trial: Silicone stents may improve patient care
Roshan Patel, MD, on the impact of restricted irrigation on PCNL outcomes
Targeted Therapy in mHSPC: Effects of Mutation Absence
Real-World Outcomes With Nadofaragene in BCG-Unresponsive NMIBC
An Overview of Nogapendekin Alfa Inbakicept for High-Risk, BCG-Unresponsive NMIBC
Treatment Strategies for Symptomatic Bone Metastases in mHSPC
Related Content
